2018 Facility and Physician Billing Guide Transcatheter Heart Valve Replacement Technologies

Total Page:16

File Type:pdf, Size:1020Kb

2018 Facility and Physician Billing Guide Transcatheter Heart Valve Replacement Technologies 2018 Facility and Physician Billing Guide Transcatheter Heart Valve Replacement Technologies Physician Inpatient Coding for TAVR Facilities and Physicians use Current Procedural Terminology (CPT1) codes to bill for procedures and services. Each CPT code is assigned unique relative value units (RVUs), which are used to determine payment by the Centers for Medicare and Medicaid Services (CMS). All the CPT codes used to bill for TAVR procedures are listed below. 2018 National Avg. Each Physician CPT Code1, 2 Description Physician Payment Payment 2018 Facility (Final JAN-DEC) (Modifier-62)* RVUs Transcatheter aortic valve replacement 33361 (TAVR/TAVI) with prosthetic valve; $1,421 $888 39.46 percutaneous femoral artery approach Transcatheter aortic valve replacement 33362 (TAVR/TAVI) with prosthetic valve; open $1,551 $969 43.08 femoral artery approach Transcatheter aortic valve replacement 33363 (TAVR/TAVI) with prosthetic valve; open $1,608 $1,005 44.68 axillary artery approach Transcatheter aortic valve replacement 33364 (TAVR/TAVI) with prosthetic valve; open $1,694 $1,059 47.06 iliac artery approach Transcatheter aortic valve replacement 33365 (TAVR/TAVI) with prosthetic valve; trans- $1,863 $1,164 51.76 aortic approach (e.g., median sternotomy, mediastinotomy) Transcatheter aortic valve replacement 33366 (TAVR/TAVI) with prosthetic valve; trans- $2,015 $1,259 55.98 apical exposure (e.g., left thoracotomy) Add-on Codes Transcatheter aortic valve replacement (TAVR/ TAVI) with prosthetic valve; cardio-pulmonary bypass support with percutaneous peripheral 33367+ arterial and venous cannulation (e.g., femoral $657 NA 18.26 vessels) (list separately in addition to code for primary procedure) 2018 National Avg. Each Physician 1, 2 2018 Facility CPT Code Description Payment Physician Payment RVUs (Final JAN-DEC) (Modifier-62)* Transcatheter aortic valve replacement (TAVR/ TAVI) with prosthetic valve; car-diopulmonary bypass support with open peripheral arterial 33368+ and venous cannulation (e.g., femoral, iliac, $781 NA 21.70 axillary vessels) (list separately in addition to code for primary procedure) Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with 33369+ central arterial and venous cannulation $1,031 NA 28.65 (e.g., aorta, right atrium, pulmonary artery) (list separately in addition to code for primary procedure) Note: *As per the CMS’s NCD for TAVR, TAVR is a two-physician (IC & CS) procedure. Medicare payment for each physician is 62.5% of the established national average payment 8. +33367,33368 and 33369 are add-on codes which does not require modifier 62 hence each physician payment of 62.5% does not apply. Note: Medicare will only pay TAVR physician claims with these CPT codes when billed with the Place of Service (POS) code 21 (Inpatient Hospital), modifier 62 (two surgeons/co-surgeons), modifier Q0 (zero) signifying CED participation (qualifying registry or qualified clinical study) and ICD-10 secondary diagnosis code Z00.6 (Encounter for examination for normal comparison and control in clinical research program) Medicare requires reporting of the Clinical Trial (CT) number on the claim form. For example, the CT number for the TVT Registry is CT01737528 and the PARTNER II Trial is CT01314313. Medicare may return other claims as unprocessable.* Codes 33361-33369 have a 0 day global period; Codes 33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368 and 33369 do not include cardiac catheterization [93451-93572] when performed at the time of the procedure for diagnostic purposes prior to aortic valve replacement. Codes 33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368 and 33369 include all other catheterization[s], temporary pacing, intraprocedural contrast injection[s], fluoroscopic radiological supervision and interpretation, and imaging guidance, which are not reported separately when performed to complete the aortic valve procedure. Additional Notes1 33361-33369 Transcatheter Aortic Valve Replacement Includes: Access and Implantation of the aortic valve (33361-33366) Access sheath placement Advancement of valve delivery system Arteriotomy closure Balloon aortic valvuloplasty Cardiac or open arterial approach Deployment of valve Percutaneous access Temporary pacemaker Valve repositioning when necessary Radiology procedures: Angiography during and after procedure Assessment of access site for closure Documentation of completion of the intervention Guidances for valve placement Supervision and interpretation Excludes: Percutaneous coronary interventional procedures Transvascular ventricular support (33967, 33970, 33973, 33975-33976, 33990-33993, 33999) Code also add-on codes for cardiopulmonary bypass, when appropriate (33367-33369) Code also cardiac catheterization services for purposes other than TAVR/TAVI Code also diagnostic coronary angiography at the same time as TAVR/TAVI when: A previous study is available, but documentation states the patient’s condition has changed since the previous study, visualization of the anatomy/pathology is inadequate, or a change occurs during the procedure warranting additional evaluation of an area outside the current target area No previous catheter-based coronary angiography study is available, and a full diagnostic study is performed, with the decision to perform the intervention based on that study Code also modifier 59 when diagnostic coronary angiography procedures are performed as separate and distinct procedural services on the same day or session as TAVR/TAVI Code also modifier 62 as well as al TAVI/TAVR procedures require the work of two physicians Do not report separately when included in the TAVR/TAVI service (93452-93453, 93458-93461, 933567) Hospital Inpatient Diagnosis and Procedure Coding Medicare inpatient hospital reimbursement is based upon the Medicare Severity Diagnostic-Related Group (MS-DRG) classification system, which assigns MS-DRGs based on ICD-9-CM diagnosis and procedure codes. The following codes generally describe diagnosis and procedures associated with the use of the Edwards SAPIEN 3 transcatheter heart valve. ICD-9-CM3 ICD-10-CM Diagnosis Description Description Code Oct. 1st, 2015) 424.1 Aortic valve disorders I35.0 Nonrheumatic aortic (valve) stenosis ICD-9-CM3 ICD-10-CM Diagnosis Description Description Code Oct. 1st, 2015) Replacement of Aortic Valve with 35.05 Endovascular replacement of aortic valve 02RF38Z Zooplastic Tissue, Percutaneous Approach Replacement of Aortic Valve with Zooplastic 35.06 Transapical replacement of aortic valve 02RF38H Tissue, Transapical, Percutaneous Approach Pursuant to the final rule for the FY 2015 hospital Inpatient Prospective Payment System (IPPS), CMS created new MS-DRGs for endovascular cardiac valve replacements, eective October 1, 2014. MS-DRG5 Description FY 2018 FY 2018 National FY 2018 Geometric Relative Weight Average Payment7 Mean-LOS 266 Endovascular Cardiac Valve 7.7516 $46,727 5.0 Replacement with MCC Endovascular Cardiac Valve 267 6.1053 $36,803 2.9 Replacement without MCC Note: Medicare will only pay TAVR facility claims with these ICD-10-CM codes when billed with the ICD-10 secondary diagnosis code Z00.6 (Encounter for examination for normal comparison and control in clinical research program) and condition code 30 (qualifying clinical trial). Medicare will return all other claims as unprocessable. Principal Diagnosis for Valve-in-Valve with the Edwards SAPIEN 3 Transcatheter Heart Valve Depending on the circumstances, there are several ICD-10-CM diagnosis codes that could be used as the principal encounter from the prior surgical valve placement. From a coding perspective, the options are following. Scenario ICD-10 Diagnosis Code ICD-10 Code Description If the previously placed valve was malpositioned Displacement of biological heart or became displaced T82.222A valve graft, initial encounter If the previously placed valve developed Stenosis of cardiac prosthetic devices, stenosis prematurely T82.857A implants and grafts, initial encounter If the previously placed valve developed Leakage of biological heart valve regurgitation prematurely T82.223A graft, initial encounter If the previously placed valve developed stenosis or regurgitation as an expected occurrence as it Encounter for adjustment and Z45.09 management of other cardiac device degenerates toward valve end-of-life Reimbursement Hotline: (303) 524-3854 or [email protected] Disclaimer Reimbursement information provided by Edwards Lifesciences is gathered from third-party sources and is presented for informational purposes only. Edwards makes no representation, warranty or guarantee as to the timeliness, accuracy or completeness of the information and such information is not, and should not be construed as reimbursement, coding or legal advice. Any and all references to reimbursement codes are provided as examples only and are not intended to be a recommendation or advice as to the appropriate code for the a particular patient, diagnosis, product or procedure or a guarantee or promise of coverage or payment, nor does Edwards Lifesciences warranty that codes listed are appropriate in all related clinical scenarios. It is the responsibility of the provider to determine if coverage exists and what requirements are necessary for submitting a proper claim for reimbursement to a health plan or payer, including the appropriate code(s) for products provided or services rendered. Laws, regulations, and payer policies concerning reimbursement are complex and change frequently; service
Recommended publications
  • Minimally Invasive Superficial Femoral Artery Endarterectomy: Early Experience with a Modified Technique
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Eur J Vasc Endovasc Surg 16, 254-258 (1998) ENDOVASCULAR AND SURGICAL TECHNIQUES Minimally Invasive Superficial Femoral Artery Endarterectomy: Early Experience with a Modified Technique M. S. Whiteley 1, T. R. Magee 1, E. P. H. Torrie 2 and R. B. Galland* Department of ~Surgery and 2Radiology, Royal Berkshire Hospital, London Road, Reading, U.K. Objectives: To describe our experience of a modified technique for carrying out remote endarterectomy for superficial femoral artery occlusive disease. Methods: A 4-French arterial dilator is inserted using a Smart needle into the popliteal artery below the occlusion. A remote endarterectomy is carried out through an arteriotomy in the proximal superficial femoral artery. The atheroma is cut distal to the lower extent of disease using a Moll ring cutter. The lower flap of atheroma is secured with an intraluminaI stent inserted from the arteriotomy in the superficial femoral artery. The arteriotomy is extended into the common femoral artery and closed with a vein patch. Results: The procedure was completed in 21 of 26 limbs. In 18 cases the superficial femoral artery remained patent at 30 days. Of the 21 cases all but four stayed in hospital for one night. A successful femoropopliteal bypass was carried out in the five patients in whom the procedure was not completed. Conclusion: Insertion of the dilator into the popliteal artery distal to the occlusion before carrying out the remote endarterectomy has two advantages. Firstly, the stent insertion is carried out in the correct plane and prevents dissection of the distal cut atheroma when attempting to pass the guidewire from above.
    [Show full text]
  • Surgical Management of Transcatheter Heart Valves
    Corporate Medical Policy Surgical Management of Transcatheter Heart Valves File Name: surgica l_management_of_transcatheter_heart_valves Origination: 1/2011 Last CAP Review: 6/2021 Next CAP Review: 6/2022 Last Review: 6/2021 Description of Procedure or Service As the proportion of older adults increases in the U.S. population, the incidence of degenerative heart valve disease also increases. Aortic stenosis and mitra l regurgita tion are the most common valvular disorders in adults aged 70 years and older. For patients with severe valve disease, heart valve repair or replacement involving open heart surgery can improve functional status and qua lity of life. A variety of conventional mechanical and bioprosthetic heart valves are readily available. However, some individuals, due to advanced age or co-morbidities, are considered too high risk for open heart surgery. Alternatives to the open heart approach to heart valve replacement are currently being explored. Transcatheter heart valve replacement and repair are relatively new interventional procedures involving the insertion of an artificial heart valve or repair device using a catheter, rather than through open heart surgery, or surgical valve replacement (SAVR). The point of entry is typically either the femoral vein (antegrade) or femora l artery (retrograde), or directly through the myocardium via the apical region of the heart. For pulmonic and aortic valve replacement surgery, an expandable prosthetic heart valve is crimped onto a catheter and then delivered and deployed at the site of the diseased native valve. For valve repair, a small device is delivered by catheter to the mitral valve where the faulty leaflets are clipped together to reduce regurgitation.
    [Show full text]
  • Severe Aortic Stenosis and the Valve Replacement Procedure
    Severe Aortic Stenosis and the Valve Replacement Procedure A Guide for Patients and their Families If you’ve been diagnosed with severe aortic stenosis, you probably have a lot of questions and concerns. The information in this booklet will help you learn more about your heart, severe aortic stenosis, and treatment options. Your heart team will recommend which treatment option is best for you. Please talk with them about any questions you have. Table of Contents 4 About Your Heart 5 What Is Severe Aortic Stenosis? 5 What Causes Severe Aortic Stenosis? 7 What Are the Symptoms of Severe Aortic Stenosis? 8 Treatment Options for Severe Aortic Stenosis 10 Before a TAVR Procedure 12 What Are the Risks of TAVR? 2 3 About Your Heart What Is Severe See the difference between healthy and The heart is a muscle about the size of your fist. It is a pump that works nonstop to Aortic Stenosis? diseased valves send oxygen-rich blood throughout your entire body. The heart is made up of four The aortic valve is made up of two or three chambers and four valves. The contractions (heartbeats) of the four chambers push Healthy Valve the blood through the valves and out to your body. tissue flaps, called leaflets. Healthy valves open at every heart contraction, allowing blood to flow forward to the next chamber, and then close tightly to prevent blood from backing Pulmonic controls the flow of Aortic controls the flow of blood up. Blood flows in one direction only. This is Valve blood to the lungs Valve out of your heart to the important for a healthy heart.
    [Show full text]
  • Targeting Endothelial Kruppel-Like Factor 2 (KLF2) in Arteriovenous
    Targeting Endothelial Krüppel-like Factor 2 (KLF2) in Arteriovenous Fistula Maturation Failure A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY (Ph.D.) in the Biomedical Engineering Program Department of Biomedical Engineering College of Engineering and Applied Science 2018 by Keith Louis Saum B.S., Wright State University, 2012 Dissertation Committee: Albert Phillip Owens III, Ph.D. (Committee Chair) Begona Campos-Naciff, Ph.D Christy Holland, Ph.D. Daria Narmoneva, Ph.D. Prabir Roy-Chaudhury, M.D., Ph.D Charuhas Thakar, M.D. Abstract The arteriovenous fistula (AVF) is the preferred form of vascular access for hemodialysis. However, 25-60% of AVFs fail to mature to a state suitable for clinical use, resulting in significant morbidity, mortality, and cost for end-stage renal disease (ESRD) patients. AVF maturation failure is recognized to result from changes in local hemodynamics following fistula creation which lead to venous stenosis and thrombosis. In particular, abnormal wall shear stress (WSS) is thought to be a key stimulus which alters endothelial function and promotes AVF failure. In recent years, the transcription factor Krüppel-like factor-2 (KLF2) has emerged as a key regulator of endothelial function, and reduced KLF2 expression has been shown to correlate with disturbed WSS and AVF failure. Given KLF2’s importance in regulating endothelial function, the objective of this dissertation was to investigate how KLF2 expression is regulated by the hemodynamic and uremic stimuli within AVFs and determine if loss of endothelial KLF2 is responsible for impaired endothelial function.
    [Show full text]
  • Transpulmonary Closure of Giant Persistent Ductus Arteriosus Under Cardiopulmonary Bypass and Normothermic Cardioplegia
    Published online: 2019-11-25 THIEME 36 TranspulmonaryPoint of Technique Closure of Giant Persistent Ductus Arteriosus Chowdhury et al. Transpulmonary Closure of Giant Persistent Ductus Arteriosus under Cardiopulmonary Bypass and Normothermic Cardioplegia Ujjwal K. Chowdhury1 Sukhjeet Singh1 Niwin George1 Lakshmi Kumari Sankhyan1 Poonam Malhotra Kapoor2 1Department of Cardiothoracic and Vascular Surgery, All India Address for correspondence Ujjwal K. Chowdhury, MCh, Institute of Medical Sciences, New Delhi, India Department of Cardiothoracic and Vascular Surgery, All 2Department of Cardiac Anaesthesia, All India Institute of Medical India Institute of Medical Sciences, New Delhi 110029, India Sciences, New Delhi, India (e-mail: [email protected]). J Card Crit Care TSS 2020;3:36–38 Abstract A 25-year-old female patient with a giant, short, calcified, hypertensive, window duc- tus arteriosus underwent successful closure via transpulmonary approach under nor- Keywords mothermic cardiopulmonary bypass without circulatory arrest using a Foley catheter ► giant ductus for temporary occlusion. arteriosus ► adult ductus ► cardiopulmonary bypass ► transpulmonary closure ► calcified ductus Introduction chylothorax, or recanalization. Postoperative computerized tomographic angiography revealed complete ductal inter‑ Despite 80 years of experience, correction of persistent duc‑ ruption with no residual shunt or ductal aneurysm (►Fig. 3). tus arteriosus remains a surgical challenge in the subset of 1. Primary median sternotomy is performed. patients
    [Show full text]
  • Surgery for Acquired Heart Disease
    View metadata, citation and similar papers at core.ac.uk brought to you byCORE provided by Elsevier - Publisher Connector SURGERY FOR ACQUIRED HEART DISEASE EARLY RESULTS WITH PARTIAL LEFT VENTRICULECTOMY Patrick M. McCarthy, MD a Objective: We sought to determine the role of partial left ventriculectomy in Randall C. Starling, MD b patients with dilated cardiomyopathy. Methods: Since May 1996 we have James Wong, MBBS, PhD b performed partial left ventriculectomy in 53 patients, primarily (94%) in Gregory M. Scalia, MBBS b heart transplant candidates. The mean age of the patients was 53 years Tiffany Buda, RN a Rita L. Vargo, MSN, RN a (range 17 to 72 years); 60% were in class IV and 40% in class III. Marlene Goormastic, MPH c Preoperatively, 51 patients were thought to have idiopathic dilated cardio- James D. Thomas, MD b myopathy, one familial cardiomyopathy, and one valvular cardiomyopathy. Nicholas G. Smedira, MD a As our experience accrued we increased the extent of left ventriculectomy James B. Young, MD b and more complex mitral valve repairs. For two patients mitral valve replacement was performed. For 51 patients the anterior and posterior mitral valve leaflets were approximated (Alfieri repair); 47 patients also had ring posterior annuloplasty. In 27 patients (5!%) one or both papillary muscles were divided, additional left ventricular wall was resected, and the papillary muscle heads were reimplanted. Results: Echocardiography showed a significant decrease in left ventricular dimensions after resection (8.3 cm to 5.8 cm), reduction in mitral regurgitation (2.8+ to 0), and increase in forward ejection fraction (15.7% to 32.7%).
    [Show full text]
  • Leapfrog Hospital Survey Hard Copy
    Leapfrog Hospital Survey Hard Copy QUESTIONS & REPORTING PERIODS ENDNOTES MEASURE SPECIFICATIONS FAQS Table of Contents Welcome to the 2016 Leapfrog Hospital Survey........................................................................................... 6 Important Notes about the 2016 Survey ............................................................................................ 6 Overview of the 2016 Leapfrog Hospital Survey ................................................................................ 7 Pre-Submission Checklist .................................................................................................................. 9 Instructions for Submitting a Leapfrog Hospital Survey ................................................................... 10 Helpful Tips for Verifying Submission ......................................................................................... 11 Tips for updating or correcting a previously submitted Leapfrog Hospital Survey ...................... 11 Deadlines ......................................................................................................................................... 13 Deadlines for the 2016 Leapfrog Hospital Survey ...................................................................... 13 Deadlines Related to the Hospital Safety Score ......................................................................... 13 Technical Assistance.......................................................................................................................
    [Show full text]
  • Transcatheter Aortic Valve Replacement
    What is TAVR? Cardiac Catheterization: Important things to know that will help you get ready Transcatheter Aortic Valve Replacement (TAVR) is a procedure Your doctor will tell if you need to stop eating or drinking to fix the aortic valve without taking out the old valve. A TAVR before your procedure. Your doctor also will tell you if you does not need open heart surgery and the heart does not need must stop taking any medications before the procedure. to be stopped. Catheterization Lab In the Pre-Operative (Pre-Op) Room before your The surgeon puts a catheter (thin tube) into an artery in your Cardiac Catheterization upper leg or through a small cut in your chest. The catheter will • You will wear a hospital gown. We will ask you to take off all Transcatheter Aortic Valve carry a new valve to your heart. your clothing (even underwear), jewelry, dentures, glasses, Replacement (TAVR) hearing aids, etc. • An intravenous line (IV) may be put into a vein in your arm • We will prepare and clean the catheter site (where the catheter goes into your body). We will clean your skin with a special wash that kills germs. We may need to trim body hair. • We will ask you to empty your bladder (pee) before your procedure After Your Cardiac Catheterization • You may be on bed rest (lying flat) for 2 to 6 hours. To lower the risk of bleeding, we do not want you to bend your body at the catheter site (where the catheter went into your body) • Your nurse will often check your vital signs (blood pressure, heart rate, temperature) and catheter site • You must use a urinal or bed pan until you can safely stand and walk to the bathroom • While you are healing, do not do strenuous exercise (such as running or lifting weights).
    [Show full text]
  • V5 Data Dictionary Supplement with Pending Data Element Updates
    V5 Data Dictionary Supplement with Pending Data Element Updates The mission of the NCDR® is to improve the quality of cardiovascular patient CathPCI by providing information, knowledge and tools; implementing quality initiatives; and supporting research that improves patient CathPCI and outcomes. The NCDR® is an initiative of the American College of Cardiology Foundation, with partnering support from the Society for Cardiovascular Angiography and Interventions for the CathPCI Registry. CONFIDENTIALITY NOTICE This document contains information confidential and proprietary to the American College of Cardiology Foundation. This document is intended to be a confidential communication between ACCF and participants of the CathPCI Registry and may involve information or material that may not be used, disclosed or reproduced without the written authorization of the ACCF. Those so authorized may only use this information for a purpose consistent with the authorization. Reproduction of any section of this document with permission must include this notice. Table of Contents Section G. Cath Lab Visit Seq#7400 Indications for Cath Lab Visit....................................................................................Page 3 Seq#7405 Chest Pain Symptom Assessment…………………………………….…………………………………..Page 5 Section I. PCI Procedure Seq#7825 Percutaneous Coronary Intervention Indication......................................................Page 6 Review of Cath Lab Indications & PCI Indications…………………………………………….….….……….…. Page 8 Section K. Intra and Post-Procedure
    [Show full text]
  • About Mitral Valve Repair
    About Mitral Valve Repair What It Is What To Expect Definition Prior to Procedure The mitral valve is on the left side of the heart. It allows Your doctor will likely do the following: blood to flow from the left upper chamber into the left • Physical exam lower chamber. When the valve is not working well, it • Chest X-ray may need to be repaired. • Lab work • Echocardiogram Reasons for Procedure • Electrocardiogram (ECG, EKG) Mitral valve repair is the best option for many patients • Cardiac catheterization with degenerative mitral valve disease leading to regurgitation (leakage). Compared to valve replacement, Talk to your doctor about your medicines, herbs, or mitral valve repair provides better outcomes leaving supplements. You may be asked to stop taking some normally functioning tissue, which resists infection more medicines up to one week before the procedure, such as: effectively and usually eliminates the need for long-term • Blood-thinning drugs, such as warfarin (Coumadin) use of blood thinners. • Anti-platelet drugs, such as clopidogrel (Plavix) • Diabetes medications, such as metformin Possible Complications (Glucophage) If you are planning to have a mitral valve repair, your doctor will review a list of possible complications, which Your doctor may also ask you to: may include: • Eat a light meal the night before. Do not eat or drink • Infections anything after midnight. • Bleeding • Arrange for a ride to and from the hospital. • Stroke • Arrange for help at home after the procedure. • Damage to other organs, such as the kidneys Anesthesia • Irregular heart rhythm You will have a general anesthetic. You will be asleep • Death during the procedure.
    [Show full text]
  • NCDR® Cathpci Registry® V4.4 Coder's Data Dictionary
    NCDR® CathPCI Registry® v4.4 Coder's Data Dictionary A. Demographics Seq. #: 2000 Name: Last Name Coding Instructions: Indicate the patient's last name. Hyphenated names should be recorded with a hyphen. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2010 Name: First Name Coding Instructions: Indicate the patient's first name. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2020 Name: Middle Name Coding Instructions: Indicate the patient's middle name. Note(s): It is acceptable to specify the patient's middle initial. If the patient does not have a middle name, leave field blank. If the patient has multiple middle names, enter all of the middle names sequentially. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2030 Name: SSN Coding Instructions: Indicate the patient's United States Social Security Number (SSN). Note(s): If the patient does not have a US Social Security Number (SSN), leave blank and check 'SSN NA'. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2031 Name: SSN N/A Coding Instructions: Indicate if the patient does not have a United States Social Security Number(SSN). Target Value: The value on arrival at this facility Selections: Selection Text Definition No Yes Supporting Definitions: (none) Effective for Patient Discharges April 1, 2011 © 2008, American College of Cardiology Foundation 1/5/2011 3:12:46 PM Page 1 of 82 NCDR® CathPCI Registry® v4.4 Coder's Data Dictionary A.
    [Show full text]
  • Heart Valve Disease
    Treatment Guide Heart Valve Disease Heart valve disease refers to any of several condi- TABLE OF CONTENTS tions that prevent one or more of the valves in the What causes valve disease? .................................. 2 heart from functioning adequately to assure prop- er circulation. Left untreated, heart valve disease What are the symptoms of heart valve disease? ....... 5 can reduce quality of life and become life-threat- How is valve disease diagnosed? ............................ 6 ening. In many cases, heart valves can be surgi- What treatments are available? .............................. 8 cally repaired or replaced, restoring normal func- What are the types of valve surgery? ...................... 9 tion and allowing a return to normal activities. What can I expect before and after surgery? .......... 13 Cleveland Clinic’s Sydell and Arnold Miller How can I protect my heart valves? ...................... 17 Family Heart & Vascular Institute is one of the largest centers in the country for the diagnosis and treatment of heart valve disease. The decision to prescribe medical treatment or proceed with USING THIS GUIDE surgical repair or replacement is based on the Please use this guide as a resource as you examine your type of heart valve disease you have, the severity treatment options. Remember, it is every patient’s right of damage, your age and your medical history. to ask questions, and to seek a second opinion. To make an appointment with a heart valve specialist at Cleveland Clinic, call 216.444.6697. CLEVELAND CLINIC | HEART VALVE DISEASE TREATMENT GUIDE About Valve Disease The heart valves How the Valves Work Heart valve disease means one of the heart valves isn’t working properly because The heart has four valves — one for of valvular stenosis (narrowing of the valves) or valvular insufficiency (“leaky” valve).
    [Show full text]